-
-
-
-
Add to Cart The item has been added13307-1A competitive inhibitor of PC-PLC (Ki = 6.4 µM) also reduces sphingomyelin synthase activity, both in membrane preparations (IC<sub>50</sub> = 100 µg/ml) and in cells has antioxidant, antiviral, and anti-tumor activities. -
Add to Cart The item has been added13307-10A competitive inhibitor of PC-PLC (Ki = 6.4 µM) also reduces sphingomyelin synthase activity, both in membrane preparations (IC<sub>50</sub> = 100 µg/ml) and in cells has antioxidant, antiviral, and anti-tumor activities. -
Add to Cart The item has been added13307-25A competitive inhibitor of PC-PLC (Ki = 6.4 µM) also reduces sphingomyelin synthase activity, both in membrane preparations (IC<sub>50</sub> = 100 µg/ml) and in cells has antioxidant, antiviral, and anti-tumor activities. -
Add to Cart The item has been added13307-5A competitive inhibitor of PC-PLC (Ki = 6.4 µM) also reduces sphingomyelin synthase activity, both in membrane preparations (IC<sub>50</sub> = 100 µg/ml) and in cells has antioxidant, antiviral, and anti-tumor activities. -
Add to Cart The item has been added17282-1A Cdc25 phosphatase inhibitor (IC<sub>50</sub> = 0.82 µM for human recombinant Cdc25B) arrests asynchronous PC-3 prostate cancer cells in G2/M phase at 20 µM. -
Add to Cart The item has been added17282-10A Cdc25 phosphatase inhibitor (IC<sub>50</sub> = 0.82 µM for human recombinant Cdc25B) arrests asynchronous PC-3 prostate cancer cells in G2/M phase at 20 µM. -
Add to Cart The item has been added17282-25A Cdc25 phosphatase inhibitor (IC<sub>50</sub> = 0.82 µM for human recombinant Cdc25B) arrests asynchronous PC-3 prostate cancer cells in G2/M phase at 20 µM. -
Add to Cart The item has been added17282-5A Cdc25 phosphatase inhibitor (IC<sub>50</sub> = 0.82 µM for human recombinant Cdc25B) arrests asynchronous PC-3 prostate cancer cells in G2/M phase at 20 µM. -
Add to Cart The item has been added17131-10A double prodrug that undergoes in vivo hydrolytic cleavage to produce dabigatran, a potent thrombin inhibitor (Ki = 4.5 nM) shows antithrombotic efficacy in animal models of thrombosis, with a rapid onset of action.
